ATGC is “A Translational Genomics Company”. ATGC founders are the first wave researchers in adopting programmable nuclease technologies into translational research. The power of ATGC’s expertise and technologies has been well recognized by the National Institutes of Health (NIH), as well as the biotech and pharmaceutical industry. In 2017 ATGC received 3 NIH STTR grant awards. ATGC is dedicated to the development of novel transgenic rabbit models for translational research and as discovery platforms for therapeutic biologics such as monoclonal antibodies.

Dr. Xia currently leads the R&D of ATGC. Prior to joining ATGC in 2017, Dr. Xia worked at Houston Methodist Hospital and was an Assistant Professor of Weill Cornell Medical College, Cornell University. Before that Dr. Xia worked at WiCell Research Institute as an Assistant Scientist. He is a World leader in genetic editing, stem cells, and has more than a decade’s experience working with transgenic animals. Dr. Xia holds a Ph.D. from Tsinghua University, Beijing, China.